Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Study discovers contraception alternative for female cats
"This breakthrough discovery is a major milestone in our quest to provide pet owners with an alternative to surgical spay and neuter" – Gary K. Michelson.
New gene therapy shown to be effective long-term.

Scientists in the USA have demonstrated that a single dose of anti-Müllerian hormone (AMH) gene therapy can produce long-term contraception in female domestic cats.

It is hoped the breakthrough in feline sterilisation will eventually aid efforts to reduce free-roaming cat populations, which can be too large for spaying to be effective. In the USA, for example, there are an estimated 600 million free-roaming domestic cats.

Researchers from the Cincinnati Zoo & Botanical Garden’s Center for Conservation and Research of Endangered Wildlife, the Massachusetts General Hospital, and Horae Gene Therapy Center treated six female cats with a single injection of an adreno-associated viral gene therapy vector with a slightly altered version of the AMH gene.

AMH is a naturally occurring hormone produced by mammals. In cats, it is secreted by ovarian follicles.

After treatment, two four-month long breeding trials were performed, the first after one year and the second after two years. Three untreated cats, used as controls, produced kittens, but none of the cats which had been treated with AMH became pregnant.

During the study, regular health checks found no adverse side effects from the treatment.

Gary K. Michelson, founder and co-chair of the Michelson Found Animals Foundation, which helped fund the study, said: “A non-surgical sterilant for community and companion animals is long overdue and will transform animal welfare. This breakthrough discovery is a major milestone in our quest to provide pet owners with an alternative to surgical spay and neuter.”

As well as helping resolve welfare issues by reducing the number of free-roaming cats, it’s also hoped that controlling numbers will benefit wildlife.

Jenny Gainer, curator of birds and African animals at Cincinnati Zoo & Botanical Garden, said: “Cat predation is a major source of mortality in wild birds. Outdoor cats also contribute indirectly through fear, resource competition, and disease transmission. Controlling and reducing the population of free-roaming cats will make a major difference for declining songbird populations.”

However, it may be a while before the gene therapy is used regularly for feline sterilisation, as there is not currently the right infrastructure in place to mass produce the treatment.

The study has been published in Nature Communications.

Become a member or log in to add this story to your CPD history

FIVP launches CMA remedies survey

News Story 1
 FIVP has shared a survey, inviting those working in independent practice to share their views on the CMA's proposed remedies.

The Impact Assessment will help inform the group's response to the CMA, as it prepares to submit further evidence to the Inquiry Group. FIVP will also be attending a hearing in November.

Data will be anonymised and used solely for FIVP's response to the CMA. The survey will close on Friday, 31 October 2025. 

Click here for more...
News Shorts
CMA to host webinar exploring provisional decisions

The Competition and Markets Authority (CMA) is to host a webinar for veterinary professionals to explain the details of its provisional decisions, released on 15 October 2025.

The webinar will take place on Wednesday, 29 October 2025 from 1.00pm to 2.00pm.

Officials will discuss the changes which those in practice may need to make if the provisional remedies go ahead. They will also share what happens next with the investigation.

The CMA will be answering questions from the main parties of the investigation, as well as other questions submitted ahead of the webinar.

Attendees can register here before Wednesday, 29 October at 11am. Questions must be submitted before 10am on 27 October.

A recording of the webinar will be accessible after the event.